search
Back to results

Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa

Primary Purpose

Latent Tuberculosis, HIV

Status
Completed
Phase
Not Applicable
Locations
South Africa
Study Type
Interventional
Intervention
QGIT
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Latent Tuberculosis focused on measuring cluster randomized trial, interferon-gamma, tuberculin test, operational comparison, cost effectiveness, qualitative evaluation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HIV-infected
  • >= 18 years of age
  • attending one of the 14 clinics during the duration of the study
  • eligible to receive TST or IPT according to South Africa guidelines

Exclusion Criteria:

  • diagnosed with active tuberculosis
  • not eligible to receive TST or IPT according to South Africa guidelines

Sites / Locations

  • Bothabelo CHC
  • Grace Mokhomo
  • Jouberton
  • Marcus Zenzile
  • NM Pretorious Gateway
  • Orkney
  • Park Street
  • Stilfontein
  • Tshepong Wellness Clinic
  • Tsholofelo
  • Boiki Tihapi
  • Potchefstroom Gateway
  • Potchefstroom
  • Steve Tshwete

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

TST only

QGIT

Arm Description

Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.

QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.

Outcomes

Primary Outcome Measures

Impact of linking QGIT with CD4 blood collection and the current standard of care process of TST in HIV clinics in South Africa on operational metrics
Time to known latent TB infection status in clinics integrating QGIT with CD4 blood draw versus clinics with current standard of care (TST only)
Time to provision of IPT for eligible patients in QGIT versus TST-only clinics
Proportion of patients with known LTBI status in QGIT and TST-only clinics
Proportion of eligible patients receiving IPT between QGIT and TST-only clinics
Proportion of eligible patients receiving a second TST or QGIT following an initial negative test
Patient-, provider-, and clinic-level factors that impact outcomes within and between arms

Secondary Outcome Measures

Cost effectiveness of implementing QGIT versus TST-only
Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa.
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of key clinic personnel
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Cost effectiveness of implementing QGIT versus TST-only
Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa.

Full Information

First Posted
April 10, 2014
Last Updated
October 2, 2019
Sponsor
Johns Hopkins University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), University of Witwatersrand, South Africa
search

1. Study Identification

Unique Protocol Identification Number
NCT02119130
Brief Title
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
Official Title
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in South Africa
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
November 1, 2014 (Actual)
Primary Completion Date
June 2018 (Actual)
Study Completion Date
May 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), University of Witwatersrand, South Africa

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to use a cluster randomized trial to compare the effectiveness of linking the Quantiferon-gold in-tube test (QGIT) with routine CD4 testing to the routine use of the tuberculin skin test (TST), the current standard of care for diagnosing latent tuberculosis infection (LTBI) in South Africa. The investigators hypothesize that QGIT clinics will identify LTBI and initiate isoniazid preventive therapy (IPT) in a higher proportion of patients and in a significantly faster timeframe. The cost-effectiveness of linking QGIT with routine CD4 compared to routine TST will also be evaluated, and the process of implementation of QGIT into the routine cluster of differentiation 4 (CD4) blood draw will be evaluated using a mixed method approach to identify steps that can be modified for future scale-up of the intervention.
Detailed Description
The investigators propose a cluster randomized trial in 16 HIV clinics in South Africa to compare time to determine LTBI status in patients in clinics using QGIT and TST and those with TST only. The investigators will take advantage of the excellent HIV services provided in South Africa and link QGIT with CD4 blood collection and provide the first evidence of an operational comparison between QGIT and TST in HIV-infected patients in a country that accounts for one-third of the HIV-related TB in the world. The QGIT study will contribute to the understanding of QGIT performance and implementation in HIV-infected individuals. Careful evaluation of the implementation and operational aspects of the program will provide useful knowledge for future scale-up in this and other HIV clinic settings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Latent Tuberculosis, HIV
Keywords
cluster randomized trial, interferon-gamma, tuberculin test, operational comparison, cost effectiveness, qualitative evaluation

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3506 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TST only
Arm Type
No Intervention
Arm Description
Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
Arm Title
QGIT
Arm Type
Experimental
Arm Description
QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
Intervention Type
Device
Intervention Name(s)
QGIT
Intervention Description
Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
Primary Outcome Measure Information:
Title
Impact of linking QGIT with CD4 blood collection and the current standard of care process of TST in HIV clinics in South Africa on operational metrics
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Time to known latent TB infection status in clinics integrating QGIT with CD4 blood draw versus clinics with current standard of care (TST only)
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Time to provision of IPT for eligible patients in QGIT versus TST-only clinics
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Proportion of patients with known LTBI status in QGIT and TST-only clinics
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Proportion of eligible patients receiving IPT between QGIT and TST-only clinics
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Proportion of eligible patients receiving a second TST or QGIT following an initial negative test
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Title
Patient-, provider-, and clinic-level factors that impact outcomes within and between arms
Time Frame
Participants will be followed for the duration of the study, an expected average of 2 years
Secondary Outcome Measure Information:
Title
Cost effectiveness of implementing QGIT versus TST-only
Description
Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa.
Time Frame
1 year
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of key clinic personnel
Description
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Time Frame
up to 6 months
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Description
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Time Frame
up to 6 months
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel
Description
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Time Frame
1 year
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Description
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Time Frame
1 year
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of clinic personnel
Description
Knowledge, attitudes and practices of clinic personnel, along with consensus regarding key factors linked to successful screening
Time Frame
2 years
Title
Attitudinal and operational factors influencing the successful implementation of QGIT versus TST diagnostic practices from the perspective of patients
Description
Patients' understandings and experiences with TB screening approaches, along with consensus regarding key factors linked to successful screening
Time Frame
2 years
Title
Cost effectiveness of implementing QGIT versus TST-only
Description
Costs and effectiveness (quality-adjusted life years) of LTBI screening and treatment with QGIT versus TST standard of care. Looking at the impact on the HIV-associated TB epidemic in South Africa under each strategy and scenarios under which QGIT is cost-effective relative to TST, and vice versa.
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV-infected >= 18 years of age attending one of the 14 clinics during the duration of the study eligible to receive TST or IPT according to South Africa guidelines Exclusion Criteria: diagnosed with active tuberculosis not eligible to receive TST or IPT according to South Africa guidelines
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan E Golub, PhD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bothabelo CHC
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Grace Mokhomo
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Jouberton
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Marcus Zenzile
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
NM Pretorious Gateway
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Orkney
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Park Street
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Stilfontein
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Tshepong Wellness Clinic
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Tsholofelo
City
Klerksdorp
State/Province
North West
Country
South Africa
Facility Name
Boiki Tihapi
City
Potchefstroom
State/Province
North West
Country
South Africa
Facility Name
Potchefstroom Gateway
City
Potchefstroom
State/Province
North West
Country
South Africa
Facility Name
Potchefstroom
City
Potchefstroom
State/Province
North West
Country
South Africa
Facility Name
Steve Tshwete
City
Potchefstroom
State/Province
North West
Country
South Africa

12. IPD Sharing Statement

Citations:
PubMed Identifier
29661197
Citation
Kerrigan D, Tudor C, Motlhaoleng K, Lebina L, Qomfu C, Variava E, Chon S, Martinson N, Golub JE. Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial. BMC Health Serv Res. 2018 Apr 16;18(1):288. doi: 10.1186/s12913-018-3088-8.
Results Reference
derived

Learn more about this trial

Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa

We'll reach out to this number within 24 hrs